Drugs Affecting Blood and Blood Formation Practice Questions

Q: A patient is started on oral warfarin therapy. Which of the following coagulation factors shows the most rapid decline in blood levels after initiation of warfarin therapy?

Protein C. **Explanation:** Warfarin acts as a Vitamin K antagonist, inhibiting the enzyme **Vitamin K Epoxide Reductase (VKOR)**. This prevents the γ-carboxylation of Vitamin K-dependent clotting factors (II, VII, IX, X) and endogenous anticoagulant proteins (Protein C and Protein S). The rate at which these factors decline in the blood depends entirely on their individual **half-lives**. * **Protein C** has the shortest half-life (approx. **6–8 hours**) among all the factors affected by warfarin. Because it disappears first, there is a transient period where the patient is actually in a "pro-thrombotic" state (hypercoagulable) because the natural anticoagulant (Protein C) is gone while the pro-coagulant factors (especially II and X) are still circulating. **Analysis of Incorrect Options:** * **Factor VII:** While Factor VII has the shortest half-life among the *clotting* factors (approx. 4–6 hours), **Protein C** is often cited as having a similarly rapid or slightly more clinically significant initial decline in the context of the "warfarin skin necrosis" phenomenon. In most competitive exams, if both are listed, Protein C is the preferred answer for the "most rapid decline." * **Factor X:** Has a moderate half-life of approximately 36–48 hours. * **Prothrombin (Factor II):** Has the longest half-life (approx. 60–72 hours) and is the last to decline. **Clinical Pearls for NEET-PG:** 1. **Warfarin-Induced Skin Necrosis:** Occurs due to the rapid depletion of Protein C, leading to microvascular thrombosis before the full anticoagulant effect is achieved. 2. **Heparin Bridge:** To prevent the above, heparin is always co-administered with warfarin ("bridging") until the INR reaches the therapeutic range. 3. **Monitoring:** Warfarin is monitored using **PT/INR** (Extrinsic pathway), primarily reflecting the decline in Factor VII initially.

Q: What is the half-life of alteplase?

6 minutes. **Explanation:** **Alteplase (rt-PA)** is a recombinant form of human tissue plasminogen activator. The correct answer is **6 minutes** (Option B). The pharmacokinetics of alteplase are characterized by a very rapid clearance from the plasma, primarily mediated by the liver. It follows a biphasic elimination pattern: the initial dominant half-life is approximately **4 to 6 minutes**, while the terminal half-life is longer (around 40 minutes). In the context of NEET-PG, the initial half-life is the standard value tested, as it dictates the clinical administration of the drug (loading bolus followed by a continuous infusion). **Analysis of Options:** * **Option A (3 mins):** Too short; while clearance is rapid, the distribution phase takes slightly longer. * **Option C & D (9 & 12 mins):** These values exceed the established initial half-life of alteplase. Drugs like **Reteplase** (13–16 mins) and **Tenecteplase** (20 mins) have longer half-lives, allowing for bolus dosing without prolonged infusion. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Alteplase is "clot-specific"; it preferentially activates plasminogen bound to fibrin, limiting systemic fibrinogenolysis compared to Streptokinase. * **Dosing:** Due to the short 6-minute half-life, it must be given as an **IV bolus followed by an infusion** to maintain therapeutic levels. * **Antidote:** In cases of severe bleeding, **Epsilon-aminocaproic acid** or **Tranexamic acid** can be used as inhibitors of fibrinolysis. * **Comparison:** Tenecteplase is the most fibrin-specific and has the longest half-life among the group.

Q: Which of the following is an indication for parenteral iron therapy?

Intolerance to oral iron. **Explanation:** Iron deficiency anemia is primarily managed with oral iron. However, **parenteral iron therapy** is reserved for specific clinical scenarios where oral administration is either impossible, ineffective, or unsafe. **Why Option B is Correct:** **Intolerance to oral iron** is the most common indication for parenteral therapy. Many patients experience significant gastrointestinal side effects (nausea, abdominal cramps, constipation, or metallic taste) that prevent them from completing the course. Other indications include malabsorption syndromes (e.g., Celiac disease, H. pylori gastritis), inflammatory bowel disease (where oral iron can exacerbate inflammation), and chronic kidney disease (CKD) patients on erythropoietin. **Analysis of Incorrect Options:** * **Option A & D:** While parenteral iron bypasses compliance issues and reduces the duration of treatment, these are not standard medical indications. Oral iron remains the first-line choice due to its safety profile and low cost. * **Option C:** This is a common misconception. Parenteral iron **does not** raise hemoglobin levels faster than oral iron; it only replenishes iron stores more rapidly. If an immediate rise in hemoglobin is required (e.g., a patient in labor or severe acute hemorrhage), **blood transfusion** is the treatment of choice. **High-Yield NEET-PG Pearls:** * **Rate of Response:** The rate of hemoglobin rise is the same for both oral and parenteral iron (approx. 0.7–1 g/dL per week). * **Dose Calculation:** The total dose of parenteral iron is calculated using the **Ganzoni Formula**: * *Total Iron Deficit (mg) = Body weight (kg) × (Target Hb - Actual Hb) × 2.4 + Iron stores (500 mg).* * **Safety:** Iron Dextran carries a risk of anaphylaxis; a **test dose** is mandatory. Newer preparations like Iron Sucrose and Ferric Carboxymaltose have a lower risk of hypersensitivity.

Q: Iron dextran preparations may be used for all the following conditions except?

Malabsorption related macrocytic anemia. The core concept behind this question is the distinction between **Microcytic** (Iron deficiency) and **Macrocytic** (Vitamin B12/Folate deficiency) anemias. **Why Option C is the Correct Answer:** Iron dextran is a parenteral iron preparation used specifically to treat **Iron Deficiency Anemia (IDA)**. Macrocytic anemia, particularly when related to malabsorption (like Celiac disease or Pernicious anemia), is typically caused by a deficiency in **Vitamin B12 or Folic acid**, not iron [1]. Administering iron dextran in this scenario is inappropriate as it does not address the underlying nutritional deficiency and carries a risk of iron overload and anaphylaxis. **Analysis of Incorrect Options:** * **Option A:** Oral iron failure (due to intolerance or non-compliance) is a primary indication for parenteral iron. * **Option B:** In cases of persistent, rapid blood loss (e.g., GI bleeds or Menorrhagia), oral iron cannot be absorbed fast enough to keep pace with the loss, necessitating IV iron dextran [2]. * **Option D:** Patients on Erythropoietin (EPO) for chronic kidney disease have a massive demand for iron to produce new RBCs [3]. Oral iron is often insufficient to meet this "functional iron deficiency," making IV iron a standard adjunct. **High-Yield Clinical Pearls for NEET-PG:** * **Test Dose:** Iron dextran requires a mandatory test dose due to the high risk of **Type I Hypersensitivity (Anaphylaxis)**. * **Calculation:** The total dose of iron required is calculated using the **Ganzoni Formula**: *Total Iron Deficit (mg) = Body weight (kg) × (Target Hb - Actual Hb) × 2.4 + Iron stores (500mg).* * **Staining:** On histology, iron is visualized using the **Prussian Blue (Perl’s) stain**.

Q: Compared to unfractionated heparin, low molecular weight heparins:

Are absorbed more uniformly when given subcutaneously.. **Explanation:** Low Molecular Weight Heparins (LMWHs), such as Enoxaparin and Dalteparin, are derived from the fractionation of Unfractionated Heparin (UFH). Their pharmacological profile offers several advantages over UFH: **1. Why Option A is Correct:** LMWHs have **superior and more predictable bioavailability** (~90%) when administered subcutaneously compared to UFH (~20-30%). This is because LMWHs have lower non-specific binding to plasma proteins, macrophages, and endothelial cells. This uniform absorption allows for **fixed weight-based dosing** without the need for constant titration. **2. Why the other options are incorrect:** * **Option B:** LMWHs have a predictable dose-response relationship; therefore, **routine laboratory monitoring (aPTT) is not required**. Monitoring (Anti-Xa levels) is only reserved for special cases like renal failure or pregnancy. * **Option C:** LMWHs exhibit **high cross-reactivity** with UFH antibodies. Therefore, they are strictly contraindicated in patients with Heparin-Induced Thrombocytopenia (HIT). Alternatives like Fondaparinux or Argatroban should be used instead. * **Option D:** LMWHs have a **lower risk of osteopenia** and osteoporosis compared to UFH, as they have less effect on osteoblast activity and bone resorption. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** LMWHs mainly inhibit **Factor Xa** (Ratio of Xa:IIa activity is 3:1), whereas UFH inhibits both Xa and IIa equally (1:1). * **Elimination:** LMWHs are primarily **renally excreted**. They are contraindicated in chronic kidney disease (CrCl <30 ml/min); UFH is preferred in such patients. * **Antidote:** Protamine sulfate completely neutralizes UFH but only **partially neutralizes** LMWH. * **Half-life:** LMWHs have a longer half-life (4–6 hours) compared to UFH (1–2 hours).

Question 1

What is the recommended level of anticoagulation for most patients, as measured by INR?

Accepted Answer

2.0-3.0

Answer

1.0-2.0

Answer

2.5-3.5

Answer

3.0-4.5

Question 2

A patient is started on oral warfarin therapy. Which of the following coagulation factors shows the most rapid decline in blood levels after initiation of warfarin therapy?

Accepted Answer

Protein C

Answer

Factor VII

Answer

Factor X

Answer

Prothrombin (Factor II)

Question 3

What is the half-life of alteplase?

Accepted Answer

6 minutes

Answer

3 minutes

Answer

9 minutes

Answer

12 minutes

Question 4

A 56-year-old man underwent a four-vessel coronary artery bypass graft procedure and was placed on prophylactic daily aspirin therapy. Aspirin has been shown to prevent recurrent myocardial infarction through its ability to inhibit the synthesis of what?

Accepted Answer

Thromboxane A2 (TXA2)

Answer

Adenosine diphosphate (ADP)

Answer

Leukotriene B4 (LTB4)

Answer

Nitric oxide (NO)

Question 5

Which of the following is an indication for parenteral iron therapy?

Accepted Answer

Intolerance to oral iron

Answer

Patient compliance

Answer

When an immediate rise in hemoglobin is required, such as in a patient in labor

Answer

To decrease the duration of oral medication

Question 6

Erythropoietin is absolutely necessary for the treatment of:

Accepted Answer

End-stage renal failure

Answer

Liver failure

Answer

Heart failure

Answer

Lung failure

Question 7

Hypercoagulability and dermal vascular necrosis are early appearing adverse effects of:

Accepted Answer

Warfarin

Answer

Clopidogrel

Answer

Heparin

Answer

Vitamin K

Question 8

In which of the following conditions is intravenous immunoglobulin therapy indicated?

Accepted Answer

Idiopathic thrombocytopenic purpura

Answer

Myasthenia gravis

Answer

Hemolytic-uremic syndrome

Answer

Multiple myeloma

Question 9

Iron dextran preparations may be used for all the following conditions except?

Accepted Answer

Malabsorption related macrocytic anemia

Answer

Iron deficiency anemia not responding to oral iron therapy

Answer

Persistent blood loss

Answer

Patients on erythropoietin therapy for chronic disease related anemia

Question 10

Compared to unfractionated heparin, low molecular weight heparins:

Accepted Answer

Are absorbed more uniformly when given subcutaneously.

Answer

Require more frequent laboratory monitoring.

Answer

Can be given to patients with heparin-induced thrombocytopenia.

Answer

Predispose to a higher risk of osteopenia.

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?